Record Chinese biotech out-licensing meets rising US scrutiny

South China Morning PostIndependentCenter5 hr. ago

A recent report highlights China's rise as a major player in global biotechnology, noting a record $110 billion in biotech out-licensing deals between January and June 2023. This growth has raised strategic concerns in the U.S., with policymakers reassessing their approach to China's increasing influence. Analysts emphasize that these developments impact more than just healthcare, affecting pharmaceutical supply chains, economic competitiveness, and national security. The U.S. is now scrutinizing foreign influence in the pharmaceutical sector, with new legislation aimed at increasing transparency and reducing reliance on Chinese products. The situation mirrors earlier concerns about China's control over critical materials like rare earth elements.

Bias read (Center): While the article discusses U.S. concerns about China's biotech advancements, it presents both sides of the issue by citing analysts' perspectives and mentioning U.S. legislative actions. There is no clear ideological leaning in the framing of the story, which focuses on the strategic implications而非